Study #2023-1035
A phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 in combination with IDE397 in subjects with advanced MTAP-null Solid Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
AMG 193, IDE397
Description
The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null solid tumors, and to evaluate the preliminary anti-tumor activity of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null Non-Small-Cell Lung Cancer (NSCLC).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
Study phase:
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-404-4637
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.